Topic: Metastatic Bladder Cancer

Rationale for Randomized Clinical Trials Investigating the Potential of BCG Vaccination in...

Tumor Subtyping: Making Sense of Heterogeneity with a Goal Toward Treatment ABSTRACT: BACKGROUND:...

Upregulated FGFR3 signaling in NMIBC and MIBC, the diagnosis and management of checkpoint inhibitor side effects in bladder cancer patients, the etiology of treatment delays in patients receiving neoadjuvant chemotherapy for MIBC, and 25-year trends in stage-specific incidence rates for bladder cancer.

Bladder Cancer Journal Vol. 6 Issue 3 The Urinary Microbiome and Bladder Cancer: Susceptibility...

Bladder Cancer Journal Vol. 6 Issue 2 Considerations about Non-Metastatic Bladder Cancer...

Bladder Cancer Journal Vol. 6 Issue 1 Chemotherapy Plus Immune Check-Point Inhibitors in...

Bladder Cancer Journal Vol. 5 Issue 4 Modeling Tumor Heterogeneity in Bladder Cancer: The Current...

Bladder Cancer Journal Vol. 5 Issue 3 CIS of the Bladder: Significance and Implications for...

Bladder Cancer Journal Vol. 5 Issue 2 Clinical Development of FGFR3 Inhibitors for the Treatment...

Bladder Cancer Journal Vol. 5 Issue 1 Systematic Review: Targeting HER2 in Bladder Cancer HER2...

Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis...